Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

mesothelioma

- PMLiVE

Merck acquires Abceutics in deal worth $208m to improve safety of ADCs

As part of the deal, Merck will gain access to the start-up’s payload selectivity enhancer technology

- PMLiVE

UK universities awarded over £58m by Cancer Research UK for clinician scientist training

The funding builds on the charity’s previous Clinical Academic Training Programme Award investment in 2019

- PMLiVE

Merck’s Keytruda regimen granted EC approval for expanded lung cancer use

The approval represents the sixth lung cancer indication for the anti-PD-1 therapy in Europe

- PMLiVE

Merck’s Winrevair granted FDA approval to treat pulmonary arterial hypertension in adults

The rare blood vessel disorder affects approximately 500 to 1,000 people in the US every year

- PMLiVE

ICR study shows how dormant breast cancer cells can be targeted to prevent relapse

Oestrogen receptor positive breast cancer accounts for up to 80% of all breast cancers cases

- PMLiVE

Merck’s pneumococcal vaccine candidate for adults shows promise in late-stage studies

V116 is designed to address the strains responsible for the majority of adult pneumococcal disease

- PMLiVE

Merck presents positive phase 3 data for Keytruda plus CRT in advanced cervical cancer

According to WHO, cervical cancer is the fourth most common cancer in women globally

- PMLiVE

Merck shares positive results for Keytruda in phase 3 bladder cancer study

About 83,000 people in the US will be diagnosed with bladder cancer in 2024

- PMLiVE

Merck shares positive results for Keytruda in phase 3 kidney cancer study

Renal cell carcinoma accounts for approximately 90% of all kidney cancer diagnoses

- PMLiVE

Bristol Myers Squibb’s subcutaneous Opdivo shows promise in kidney cancer

More than 430,000 new cases of renal cell carcinoma are diagnosed globally every year

- PMLiVE

BMS announces CHMP recommendation for multiple myeloma therapy Abecma

More than 50,000 cases of the blood cancer are diagnosed in Europe every year

- PMLiVE

BMS, Exelixis and Ipsen announce positive four-year results for kidney cancer regimen

More than 430,000 new cases of renal cell carcinoma are diagnosed globally every year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links